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The epididymal soluble prion protein forms a high-molecular-mass complex in
association with hydrophobic proteins
Abstract
We have shown previously that a 'soluble' form of PrP (prion protein), not associated with membranous
vesicles, exists in the male reproductive fluid [Ecroyd, Sarradin, Dacheux and Gatti (2004) Biol. Reprod. 71,
993-1001]. Attempts to purify this 'soluble' PrP indicated that it behaves like a high-molecular-mass
complex of more than 350 kDa and always co-purified with the same set of proteins. The main associated
proteins were sequenced by MS and were found to match to clusterin (apolipoprotein J), BPI (bacterial
permeability-increasing protein), carboxylesterase-like urinary excreted protein (cauxin), betamannosidase and beta-galactosidase. Immunoblotting and enzymatic assay confirmed the presence of
clusterin and a cauxin-like protein and showed that a 17 kDa hydrophobic epididymal protein was also
associated with this complex. These associated proteins were not separated by a high ionic strength
treatment but were by 2-mercaptoethanol, probably due to its action on reducing disulphide bonds that
maintain the interaction of components of the complex. Our results suggest that the associated PrP
retains its GPI (glycosylphosphatidylinositol) anchor, in contrast with brain-derived PrP, and that it is
resistant to cleavage by phosphatidylinositol-specific phospholipase C. Based on these results, the
identity of the associated proteins and the overall biochemical properties of this protein ensemble, we
suggest that 'soluble' PrP can form protein complexes that are maintained by hydrophobic interactions, in
a similar manner to lipoprotein vesicles or micellar complexes.
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The epididymal soluble prion protein forms a high-molecular-mass complex
in association with hydrophobic proteins
Heath ECROYD*1 , Maya BELGHAZI†, Jean-Louis DACHEUX* and Jean-Luc GATTI*2
*Gamète Male et Fertilité, Institut National de la Recherche Agronomique, INRA-Nouzilly, 37380 Monnaie, France, and †Service de Spectrométrie de Masse pour la Protéomique,
UMR 6175, INRA-CNRS-Haras Nationaux-Université de Tours, Station de Physiologie de la Reproduction et des Comportements, Institut National de la Recherche
Agronomique, INRA-Nouzilly, 37380 Monnaie, France

We have shown previously that a ‘soluble’ form of PrP (prion protein), not associated with membranous vesicles, exists in the male
reproductive fluid [Ecroyd, Sarradin, Dacheux and Gatti (2004)
Biol. Reprod. 71, 993–1001]. Attempts to purify this ‘soluble’
PrP indicated that it behaves like a high-molecular-mass complex
of more than 350 kDa and always co-purified with the same set of
proteins. The main associated proteins were sequenced by MS and
were found to match to clusterin (apolipoprotein J), BPI (bacterial
permeability-increasing protein), carboxylesterase-like urinary
excreted protein (cauxin), β-mannosidase and β-galactosidase.
Immunoblotting and enzymatic assay confirmed the presence of
clusterin and a cauxin-like protein and showed that a 17 kDa
hydrophobic epididymal protein was also associated with this
complex. These associated proteins were not separated by a high
ionic strength treatment but were by 2-mercaptoethanol, probably

due to its action on reducing disulphide bonds that maintain the
interaction of components of the complex. Our results suggest that
the associated PrP retains its GPI (glycosylphosphatidylinositol)
anchor, in contrast with brain-derived PrP, and that it is resistant to
cleavage by phosphatidylinositol-specific phospholipase C. Based
on these results, the identity of the associated proteins and the
overall biochemical properties of this protein ensemble, we suggest that ‘soluble’ PrP can form protein complexes that are maintained by hydrophobic interactions, in a similar manner to lipoprotein vesicles or micellar complexes.

INTRODUCTION

treatment with Triton X-114, suggesting that it may retain its GPI
anchor [13]. It is of importance to understand the mechanism
by which this ‘membrane’-associated protein is able to exist in a
‘soluble’ state in this fluid, since the transport of PrP in body fluids
may be a key event in the transmission and progression of TSEs.

PrPC (cellular PrP, where PrP stands for prion protein) is a glycoprotein of unknown function, highly conserved among mammalian species [1]. This ubiquitous protein is found in almost
all tissues, where it is usually attached to the external face of
cell membranes by a GPI (glycosylphosphatidylinositol) anchor
[2]. The conformational conversion of PrPC into its pathological
isoform (PrPSC , transconformational form of PrPC ) is thought
to be responsible for the progression of TSEs (transmissible
spongiform encephalopathies), such as BSE (bovine spongiform
encephalopathy), scrapie in sheep and Creutzfeldt–Jakob disease
in humans [3,4]. Infection can be mediated, devoid of nucleic
acid, by passage of PrPSC from host to host, provided they contain
a functional Prnp gene (protein-only hypothesis) [4–6]. The biochemical basis for the conversion of PrPC into PrPSC remains
unknown: it has been suggested that it is an autocatalytic process;
however, its interaction with an unidentified factor (named protein
‘X’) has also been proposed [7].
PrP has been found in multiple circulating isoforms in different
body fluids [8–12], and a proportion of this PrP has been shown
to be associated with exosome-like membranous vesicles [13,14].
In vitro, PrP can be released from the cell surface via the action of exogenous bacterial PI-PLC (phosphatidylinositol-specific
phospholipase C). However, we have shown that a non-membranous ‘soluble’ form of PrP is present in the male reproductive
fluid, which partitions into the detergent-rich phase following

Key words: cauda epididymal plasma, clusterin, epididymis,
glycosylphosphatidylinositol (GPI) anchor, hydrophobic protein,
prion protein (PrP).

MATERIALS AND METHODS
Reagents and antibodies

Unless otherwise specified, all chemicals were purchased from
Sigma–Aldrich (St Quentin Fallavier, France). Purified recombinant ovine PrP was a gift from Dr D. Marc (INRA,
Nouzilly, France). The mouse monoclonal antibody (P4) was
donated by Dr M. Groschup (Institute for Novel and Infectious
Emerging Diseases, Greifswald-Insel Riems, Germany) [15]. The
anti-PrP polyclonal antibody, 172 antibody, was raised against
the complete ovine recombinant PrP protein and has already been
characterized [13]. The anti-CRD antibody (where CRD stands
for cross-reacting determinant) and its positive control [phospholipase C-solubilized porcine MDP (where MDP stands for membrane dipeptidase)] were gifts from Professor N. Hooper (School
of Biochemistry and Microbiology, University of Leeds, Leeds,
U.K.) [16,17]. The full-length polyclonal anti-cauxin antibody
was a gift from Dr T. Yamashita (Department of Agro-bioscience, Iwate University, Morioka, Japan) [18]. The anti-17 kDa
polyclonal antibody has already been described [19].

Abbreviations used: BPI, bacterial permeability-increasing protein; BSE, bovine spongiform encephalopathy; CEP-HSS, cauda epididymal plasma highspeed supernatant; CRD, cross-reacting determinant; GPI, glycosylphosphatidylinositol; MALDI–TOF-MS, matrix-assisted laser-desorption ionization–timeof-flight MS; MDP, membrane dipeptidase; p -NPA, p -nitrophenylacetate; PrP, prion protein; PrPC , cellular PrP; PrPSC , transconformational form of PrPC ;
PI-PLC, phosphatidylinositol-specific phospholipase C; SOD, superoxide dismutase; TSE, transmissible spongiform encephalopathy.
1
Present address: School of Chemistry and Physics, The University of Adelaide, 5005 SA, Australia.
2
To whom correspondence should be addressed (email gatti@tours.inra.fr).
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Biological samples

Experiments on animals were conducted according to the International Guiding Principles for Biomedical Research Involving
Animals as promulgated by the Society for the Study of Reproduction. Cauda epididymal fluid was collected from adult Ile de
France or Romanov rams as described previously [8,20]. Spermatozoa were separated from the fluid by centrifugation (5000 g,
10 min and 4 ◦C), the fluid was collected, centrifuged again
(15 000 g, 10 min and 4 ◦C) and then ultracentrifuged at
45 000 g for 2 h at 4 ◦C in order to remove the exosome-like
vesicles (epididymosomes) present in this fluid [13]. This fluid
sample is referred to as CEP-HSS (cauda epididymal plasma
high-speed supernatant) throughout the text. In some experiments,
the supernatant after this ultracentrifugation was ultracentrifuged
again at 120 000 g for 2 h at 4 ◦C. The fluids were then stored at
4 ◦C. Samples were mixed with an equal volume of reducing
sample buffer [62.5 mM Tris/HCl, pH 6.8, 2 % (w/v) SDS,
0.025 % Bromophenol Blue, 10 % (v/v) glycerol and 2.5 % (v/v)
2-mercaptoethanol], such that the final concentration of 2-mercaptoethanol was 2.5 %, and then heated (95 ◦C, 5 min) before
loading on to gels.
Purification

The CEP-HSS was purified by two successive rounds of column chromatography using an HPLC system (Prosys; Biosepra,
Villeneuve-la-Garenne, France). CEP-HSS (5 ml) was concentrated 2-fold with a 10 kDa cut-off membrane before loading on to
a gel-filtration column (Hiload 16/60, Superdex 200; Pharmacia,
St Quentin en Yvelines, France). Elution was carried out at a
flow rate of 0.7 ml/min with 300 mM NaCl and 50 mM Tris/HCl
(pH 7.5) buffered solution. PrP-positive fractions (determined by
immunoblotting) were pooled, dialysed against 50 mM Tris/HCl
(pH 7.5) and loaded on to a cation-exchange chromatography
column (Q-Hyper-D, 10 mm × 150 mm; Biosepra) equilibrated
with the same buffer. Elution was performed with a 0–300 mM
NaCl linear gradient (1 ml/min) applied for 60 min. PrP-positive
fractions were again determined by immunoblotting, pooled,
dialysed and then concentrated before being used in the sucrosedensity gradients and centrifugation experiments (see below).
Calibration of the gel-filtration Superdex 200 column was performed with a calibration kit (gel filtration standards; 670, 158,
44, 17.5 and 1.3 kDa) (Bio-Rad Laboratories, Marnes la Coquette,
France).

ments, the calcium-binding properties of proteins in the complex
were examined by including 2 mM EGTA or 1 mM CaCl2 in the
sample buffer. Samples mixed with non-reducing sample buffer
were not boiled before loading on to the gels. SDS/PAGE was performed on 6–16 % gradient gels and proteins were semi-dry transferred to nitrocellulose for 2 h at 0.8 mA/cm2 . All membranes
were stained with Ponceau Red to visualize the proteins on the
membrane, rinsed in TBS (Tris-buffered saline; 50 mM Tris/HCl
and 150 mM NaCl, pH 7.6) containing 0.05 % Tween 20 (TBS-T)
and then blocked with TBS-T supplemented with either 5 % (w/v)
skimmed milk powder (anti-PrP and anti-clusterin antibodies)
or 3 % (w/v) BSA (anti-cauxin antibody). The membranes were
rinsed and incubated in TBS-T containing either 5 % skimmed
milk powder or 1 % BSA and primary antibodies (172, P4
and anti-17 kDa: 1:4000; anti-cauxin: 1:5000; and anti-clusterin:
1:10 000) overnight at 4 ◦C. The peroxidase-conjugated secondary
antibodies used were goat anti-rabbit (1:5000; Sigma–Aldrich) or
goat anti-mouse (1:5000; Jackson Immunoresearch Laboratories,
West Grove, PA, U.S.A.). Immunoblotting with the anti-CRD
antibody was performed as described previously [16,22]. The
immunoreactive proteins were detected using a chemiluminescent
substrate according to the manufacturer’s instructions (West-dura;
Pierce, Rockford, IL, U.S.A.) and the images were recorded on an
image analysis station, or by exposing the membranes to a film. No
reactive bands were found when the membranes were incubated
with the secondary antibodies alone (results not shown). In some
cases, after probing with the anti-CRD antibody, membranes were
stripped [2 % SDS, 5 % (w/v) 2-mercaptoethanol and 62.5 mM
Tris, pH 6.8] (1 h, 60 ◦C), washed with TBS and then probed with
an anti-PrP antibody (172 antibody).
Non-reducing/reducing PAGE

In some experiments, an aliquot of the purified complex was
mixed with an equal volume of non-reduced sample buffer and
non-reducing/reducing PAGE was performed essentially as described previously [23]. Briefly, after subjecting the non-reduced
fraction to electrophoresis in the first dimension, the gel lane containing the separated proteins was cut and immersed in SDS
sample buffer containing 2.5 % (w/v) 2-mercaptoethanol for
20 min at room temperature (22 ◦C) with constant agitation. Each
gel lane was then applied horizontally on top of another 6–16 %
gel, covered with reduced sample buffer and electrophoresis was
performed in the second dimension. The gel was then silverstained.

Sucrose-density-gradient ultracentrifugation

MS amino acid sequence analysis

Aliquots of CEP-HSS and the pooled and concentrated PrP positive sample following the two-step HPLC purification were applied to the top of a 5–20 % (w/v) linear sucrose gradient (prepared
in PBS with protease inhibitors) (protease inhibitor cocktail;
Sigma–Aldrich). The gradients were centrifuged at 160 000 g for
approx. 16 h at 4 ◦C in a Beckman SW41 swing-out rotor and separated into 17 fractions (0.7 ml/fraction). An aliquot of each fraction was mixed with reducing sample buffer, heated (95 ◦C,
5 min) and loaded on to the gels. Equivalent PrP-positive fractions (collected from the sucrose gradients overlaid with the
HPLC-purified samples) were pooled and used in subsequent experiments.

The identification of the major protein spots from one- and twodimensional gels was obtained by MS. The Coomassie Bluestained spots were cut with a sterile scalpel blade into small
blocks. The blocks were rinsed, then reduced and alkylated with
iodoacetamide and incubated overnight at 37 ◦C in a microtube
with 12.5 ng/µl of trypsin (sequencing grade; Roche, Meylan,
France) in 25 mM NH4 HCO3 as described previously [24]. The
tryptic fragments were extracted, dried, reconstituted with 0.1 %
formic acid and sonicated for 10 min.
Tryptic peptides were analysed either directly by MALDI–
TOF-MS (matrix-assisted laser-desorption ionization–time-offlight MS; M@LDI-L/R; Waters Micromass, Manchester, U.K.)
or sequenced by nano-LC-MS/MS (Q-TOF-Global equipped
with a nano-electrospray ionization source; Waters Micromass)
in automatic mode. The peptides were loaded on to a C18
column (AtlantisTM dC18; 3 µm, 75 µm × 150 mm NanoEaseTM ,
Waters Micromass) and eluted with a 5–60 % linear gradient
in 30 min at a flow rate of 180 nl/min [buffer A, water/acetonitrile (98/2, v/v), 0.1 % formic acid; buffer B, water/acetonitrile

Gel electrophoresis and immunoblotting

The methods of isoelectric focusing and SDS/PAGE were the
same as those described previously [21]. Before loading on to gels,
samples were mixed with non-reducing sample buffer [62.5 mM
Tris/HCl, pH 6.8, 2 % (w/v) SDS, 0.025 % Bromophenol Blue
and 10 % (v/v) glycerol] or reducing sample buffer. In other experi
c 2005 Biochemical Society
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(20/80, v/v), 0.1 % formic acid]. The peptide masses and
sequences obtained were either matched automatically to proteins
in a non-redundant database (NCBI) using the Mascot program
(http://www.matrixscience.com) or de novo sequenced using the
ProteinLynx Global Server program (Waters Micromass) and
blasted manually against the current databases (http://npsa-pbil.
ibcp.fr/cgi-bin/npsa automat.pl?page=/NPSA/npsa blast.html).
Enzyme assays

Aliquots (20 µl) of each fraction from the sucrose gradients overlaid with the HPLC-purified fraction were assayed for esterase
activity against p-NPA ( p-nitrophenylacetate) and SOD (superoxide dismutase) activity using the xanthine (5 mM) and
xanthine oxidase (1.0 unit)-based system for production of superoxide anion. Esterase activity assays were conducted in 50 mM
Tris/HCl (pH 8.0) as described previously [25]. Esterase
(0.02 unit) from porcine liver was used as a positive control. SOD
activity was investigated by monitoring Nitro Blue Tetrazoliumbased formazan formation. The SOD activity was calculated as
the percentage inhibition of the formazan produced in the control
reaction without SOD or fraction aliquots. SOD (0.5 unit) from
bovine liver was used as a positive control for this assay. Both
assays were performed in duplicate and values corrected against
parallel controls.
Ionic strength treatment

An aliquot (200 µl) of the purified complex was added to the filter
cup of a 0.5 ml concentrator equipped with a 100 kDa cut-off
membrane and centrifuged at 5000 g until 10 µl of concentrate
remained in the cup. The filtrate was retained, the volume in the
filter cup made back up to 200 µl with 125 mM NaCl and 50 mM
Tris/HCl (pH 7.5) and the sample carefully mixed and centrifuged
again. This procedure was repeated using Tris buffer containing
increasing amounts of NaCl up to a maximum of 1 M. Finally, the
volume in the filter cup was made back up to 200 µl using 50 mM
Tris/HCl (pH 7.5) containing 2 % (v/v) 2-mercaptoethanol, the
sample centrifuged and the filtrate retained. An aliquot of each recovered filtrate was mixed with reducing sample buffer, heated
(95 ◦C, 5 min) and loaded on to the gels.
Treatment with PI-PLC

In these experiments, the brains from scrapie-infected mice were
used as a positive control for GPI-anchored PrP. Brain samples
were homogenized in a 10 % (w/v) lysis solution [26]. The CEPHSS, purified complex and brain homogenate were incubated for
3 h at 37 ◦C in the presence of 1 unit/ml Bacillus cereus PI-PLC
using a method similar to that described previously [2,17]. In some
experiments, the samples were then subjected to Triton X-114
phase partitioning as described in [22]. Otherwise, the reaction
was stopped by addition of reducing sample buffer and heating
the samples at 95 ◦C for 5 min.
RESULTS
Soluble PrP from the male reproductive fluid is part of a highmolecular-mass complex

We have previously reported that PrP is present in significant
quantities in male reproductive fluid, where it can be associated
with exosome-like membrane vesicles or in a ‘soluble’ circulating
form [8,13]. Figure 1(A) shows that PrP remained in the fluid
phase of the CEP (cauda epididymal plasma) even after centrifugation at 45 000 and 120 000 g, treatments that should completely remove all the vesicular materials from this fluid. Since
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we found no differences in the quantity or forms of PrP present
in the supernatants following either of these ultracentrifugation
steps, we used the 45 000 g high-speed supernatant (CEP-HSS)
in the rest of the experiments described herein, unless otherwise
stipulated.
In an attempt to purify this ‘soluble’ PrP, the CEP-HSS was separated by gel-filtration chromatography (Figure 1B). Eight main
protein peaks were obtained and immunoblotting with a PrPspecific antibody showed that the majority of the PrP eluted in
the second protein peak (fractions 15–19; Figure 1B). These
fractions correspond to high-molecular-mass species of approx.
350–400 kDa, much heavier than the molecular mass of the
‘soluble’ PrP as judged by SDS/PAGE (43 kDa). This difference
was not due to a self-association or an aggregation of the PrP,
since after SDS/PAGE under non-reducing conditions the 43 kDa
immunoreactive band was unchanged in these fractions (results
not shown). Since a number of other proteins were also detected
in these PrP-positive fractions, we conducted a second ionexchange-based HPLC purification step on these pooled and
concentrated PrP-positive fractions.
Cation-based ion-exchange HPLC resulted in two peaks, a
minor peak at approx. 100–110 mM NaCl (fractions 13–15) and
a major peak at approx. 120–170 mM NaCl (fractions 16–23;
Figure 1C). Immunoblotting with the anti-PrP antibody showed
reactivity in fractions 18–23, corresponding to the main protein
peak. A similar pattern of protein was obtained when we reversed
the order of the HPLC purification steps (results not shown), suggesting that the co-eluting proteins may be associated with PrP as
part of a high-molecular-mass complex.
In order to confirm the existence of this complex, we subjected
the final HPLC-purified PrP-containing fractions to sucrosegradient ultracentrifugation. Figure 2(A) shows that almost all
of the proteins found to co-elute with PrP following the HPLC
purification steps also sedimented to the same fractions of the
sucrose-gradient. Approximately 11 main protein bands were
detected by silver staining, ranging in mass from approx. 10 to
150 kDa. The protein peak was found in fractions 7 and 8: PrP reactivity reflected this protein distribution with a peak of reactivity
in these same fractions. These fractions correspond to approx. 11–
13 % (w/v) sucrose (d 1.042–1.051). A sucrose-gradient sedimentation using CEP-HSS showed an identical profile of PrP
reactivity (Figure 2B) with a peak in fraction 7 corresponding
to the same density range, indicating that the complex is present
in vivo and is not induced by the conditions used during the
purification steps. Furthermore, when purified recombinant PrP
was applied to the top of a sucrose gradient and subjected to the
same centrifugation procedure, it was found in the top fraction
recovered from the gradient (results not shown).
Identification of proteins that are part of the highmolecular-mass complex

The purified protein complex recovered from the sucrose gradient
was separated by two-dimensional SDS/PAGE (Figure 3). The
main proteins were found to have acidic pI values, ranging from
4.0 to 6.8, and were found to be composed of trains of several spots
corresponding to isoforms of differing molecular mass and/or pI.
Coomassie Blue staining of the two-dimensional polyacrylamide
gels revealed at least six main protein spots and/or trains (labelled
1–6 in Figure 3). Immunoblotting of transferred proteins with the
anti-PrP antibody showed PrP as a smearing spot with an acidic
pI of approx. 4.5 and mass of 40–43 kDa. Protein spots corresponding to PrP could not be visualized even after silver staining.
The six main protein trains were excised from the gel, digested
with trypsin and MS-based protein identification was performed

c 2005 Biochemical Society
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Purification of soluble PrP from male reproductive fluid by successive rounds of HPLC

(A) Centrifuged fluid collected from the cauda epididymis (15 000 g ) was further centrifuged at 45 000 and 120 000 g . An equivalent aliquot from each supernatant was separated by SDS/PAGE,
transferred on to nitrocellulose and immunoblotted with an anti-PrP antibody. (B) Coomassie Blue staining and immunoblotting of fractions collected after gel-filtration HPLC of CEP-HSS. The
elution profile from the Superdex 200 column is shown and the shaded region indicates the fractions that were loaded on to the gel. (C) Coomassie Blue staining and immunoblotting of fractions
collected after cation-exchange HPLC of the pooled positive fractions from the gel-flitration HPLC. The elution profile from the Q-Hyper-D column is shown. The presence of PrP in these HPLC
fractions was tested by immunoblotting with an anti-PrP antibody. For all the experiments, SDS/PAGE (6–16 % polyacrylamide) and P4 (1:4000) were used.

on the peptide fragments (Table 1). From this analysis, we
have identified proteins matching to clusterin (apolipoprotein J)
(covering trains 1 and 2), BPI (bacterial permeability increasingprotein), β-mannosidase, β-galactosidase and carboxylesteraselike urinary excreted protein (cauxin) as the main proteins copurifying with PrP reactivity. Table 1 shows the peptide sequences
obtained that were matched to each protein. Similar results
were obtained when we used the excised bands from a onedimensional SDS/polyacrylamide gel to identify these proteins.
No supplementary bands could be identified.
Clusterin and cauxin are associated with PrP in male
reproductive fluid

We confirmed the presence of both clusterin and a cauxin-like
protein in the complex by immunoblotting with specific antibodies. First, clusterin reactivity was found to be present in the
same fractions as PrP following gel-filtration HPLC (fractions 15–
23; Figure 4A), ion-exchange HPLC (fractions 18–23; Figure 4B)
and sucrose-gradient ultracentrifugation of the HPLC-purified
sample (fractions 5–10; Figure 4C). Clusterin reactivity was also
detected in later fractions following the gel-filtration HPLC (Fig
c 2005 Biochemical Society

ure 4A), suggesting that not all the clusterin interacts with PrP.
Reactivity against the anti-cauxin antibody was also found in fractions 5–10 recovered from the sucrose gradient overlaid with the
HPLC-purified sample (Figure 5A). We then tested whether
the esterase activity of the cauxin-like protein was retained
within the PrP-associated complex. Esterase activity was detected
in fractions 5–11 with a peak of activity in fractions 6–8 (Figure 5B). These fractions corresponded to those in which PrP was
found (see Figure 2A).
As some studies have reported SOD activity of PrP [26,27], we
also tested whether the PrP-associated complex had such activity.
Using a xanthine–xanthine oxidase-based assay system, we found
no evidence for SOD-type activity in any of the fractions isolated
from the sucrose gradient, including those containing PrP (results
not shown).
A hydrophobic 17 kDa fluid antigen is also part of the
protein complex

During the purification of this protein complex, we observed
that two proteins of 23 and 17 kDa (see Figure 1C) had similar
properties (highly hydrophobic and similar molecular masses)

Soluble prion protein is part of a high-molecular-mass structure
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Table 1 Summary of proteins identified as being part of the soluble PrPassociated high-molecular-mass complex in male reproductive fluid

Figure 2

Sucrose-gradient sedimentation analysis of soluble PrP

Spot no. Protein

NCBI
accession no.

Peptides
matching
protein (n )

1 and 2

Clusterin

P17697

9

3

BPI

P17453

6

4

β-Mannosidase
precursor

Q29444

7

5

Carboxylesterase-like
urinary protein
(cauxin)
β-Galactosidase
precursor

BAC22577

3

P23780

5

6

TPYHFPTMEFTENNDR
LYDQLLQSYQQK
QIKTQIEQTNEER
GSLFFNPK
KLLLSSLEEAKK
RPQDTQYYSPFSSFPR
LYDQLLQSYQQK
ASSIMDELFQDRFFLR
DKELQEMSTEGSK
ICEVVTSTVSSK
LQPYFQTLPVTTK
TNPGIVAR
GLDYACQQGVLTLQK
LDKVAGVDYSLVAPPR
GEFFSLAHR
INGLPIFLK
FSDNGFLMTEK
FNNLDYR
TETEFYRR
IESSFDVVSSK
FQSPVVYANQR
GSNWIPADSFQDR
YWANFAR
FVFGGAFLK
LGIFGFFDTGDEHAR
QYFGYVLYR
VPEGPIPPSTPK
FLKDGQPFR
FYWEDR
YISGSIHYFR

(A) The pooled and concentrated HPLC-purified sample (1 ml) and (B) initial CEP-HSS
(1 ml) were separated by centrifugation through a 5–20 % (w/v) linear sucrose gradient. The
gradients were collected into 17 fractions (fraction 17, bottom). An aliquot of the first 13 fractions
was separated by SDS/PAGE and the gel was silver-stained (A) or stained with Coomassie
Blue (B). Equivalent gels for each gradient were transferred on to nitrocellulose and immunoblotted with the P4 anti-PrP monoclonal antibody.

Figure 4

Peptide sequences

Co-purification of clusterin with soluble PrP

The fractions collected following (A) gel-filtration HPLC, (B) cation-exchange HPLC and
(C) sucrose-gradient ultracentrifugation were immunoblotted with an anti-clusterin antibody
(1:10 000) as described in the Materials and methods section. Below each panel, the fractions
containing PrP reactivity are indicated (+) (same fractions as in Figures 1A, 1B and 2A
respectively).

Figure 3 Two-dimensional PAGE analysis of proteins associated with
soluble PrP
Proteins found to co-purify with PrP were subjected to two-dimensional-PAGE as described in
the Materials and methods section. (A) The major proteins visible following Coomassie Blue
staining of the gel are shown. These proteins are numbered according to their subsequent
analysis by MALDI–TOF-MS and nano-LC-MS/MS. (B) An equivalent two-dimensional gel was
transferred on to nitrocellulose and immunoblotted with the P4 anti-PrP antibody.

to epididymal fluid proteins that we have already characterized
but did not match to any protein present in the current databases
[19]. Using an antibody directed against the 17 kDa protein, we
confirmed its presence in the purified complex (Figure 6).

Further characterization of the PrP-associated
high-molecular-mass complex

We conducted studies to determine the manner by which members
of the complex interacted. We firstly looked at the role of ionic
interactions. Figure 7 shows that up to 0.75 M NaCl failed to
cause the dissociation of PrP and clusterin, and their subsequent
detection in the filtrate through a 100 kDa cut-off membrane. A
high concentration of NaCl (1 M) resulted in only a small amount
of PrP being detected in the filtrate. Addition of the reducing agent

c 2005 Biochemical Society
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Figure 7 Effect of ionic strength and reducing conditions on the stability of
the PrP-associated complex

Figure 5 Association of the cauxin-like protein with the PrP-associated
high-molecular-mass complex

The purified complex was added to the cup of a filter device equipped with a 100 kDa
cut-off membrane and treated with increasing concentrations of NaCl (0–1 M) and then
2-mercaptoethanol (see the Materials and methods section). After each centrifugation, the filtrate
was collected. These filtrates were then separated by SDS/PAGE, transferred on to nitrocellulose
and probed with the anti-PrP or anti-clusterin antibody.

(A) Fractions 1–14 recovered from the sucrose gradient overlaid with the HPLC-purified product
were immunoblotted with an anti-cauxin antibody (1:10 000) as described in the Materials and
methods section. The fractions containing PrP reactivity are marked with ‘+’ (same fractions as
in Figure 2A). (B) Fractions 1–17 from this same sucrose gradient were assayed for esterase
activity against p -NPA. Esterase activity was measured as the increase in A 405 per min and is
reported in arbitrary units. The positive control (+ ve Ctrl) consisted of 0.02 unit of porcine liver
esterase.

Figure 6
complex

A 17 kDa hydrophobic protein is part of the high-molecular-mass

Aliquots of the CEP, CEP-HSS and purified PrP-associated complex (Cmplx) were separated by
SDS/PAGE, transferred on to nitrocellulose and probed with an antibody directed against the
17 kDa protein.

(2-mercaptoethanol) was able to disrupt the complex and resulted
in PrP and clusterin both passing through the membrane.
We further examined the effect of reducing disulphide bonds
of proteins in the complex by successive non-reducing/reducing
SDS gels. When no disulphide bonds are involved in maintaining
the structure or multimeric form of a protein, it migrates through
an SDS/polyacrylamide gel at the same molecular mass under
non-reduced and reduced conditions: it is therefore found on
the diagonal after staining (Figure 8A). However, some proteins
were displaced from this diagonal; these included the following.
(i) A major protein of approx. 60–70 kDa (reduced) that migrated
in multiple forms of approx. 150 and 80 kDa under non-reducing
conditions. This protein was found to correspond to the cauxinlike protein (Figure 8B). (ii) A protein that migrated at approx.
100 kDa under non-reducing conditions and at 75 kDa under
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Figure 8 Disulphide bonding within the PrP-associated high-molecularmass complex
(A) Non-reducing/reducing SDS/PAGE analysis of the PrP-associated complex was performed
by sequentially resolving the proteins under non-reducing and reducing SDS/PAGE (see the
Materials and methods section). A one-dimensional separation of the same sample under
non-reducing and reducing conditions is shown on the top and left-hand side of the gel
respectively. (B) Silver staining and SDS/PAGE (6–16 % polyacrylamide) of the PrP-associated
complex were conducted under either non-reducing or reducing conditions and then transferred
on to nitrocellulose and probed with one among anti-PrP, anti-clusterin and anti-cauxin
antibodies.

reducing conditions. This protein which was not identified. (iii) A
40–35 kDa reduced protein, which migrated at approx. 75 kDa
under non-reducing conditions and corresponded to clusterin
(Figure 8B). Immunoblotting with the anti-PrP antibody showed
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scrapie-infected sheep were treated with PI-PLC and run on the
same gel, the characteristic upshift in the GPI-anchorless form
could be detected [2,28], in particular in the non-glycosylated
25 kDa form (Figure 9B). Also, when we conducted experiments
aimed at removing any lipid from the inositol ring prior to PIPLC treatment, the PrP remained unreactive with the anti-CRD
antibody (results not shown).

DISCUSSION

Figure 9 Soluble PrP from the male reproductive fluid has a PI-PLCresistant GPI anchor
CEP-HSS and brain homogenate from scrapie-infected mice were incubated in the presence
of PI-PLC. (A) The CEP-HSS (Sup) treated with PI-PLC was subjected to Triton X-114
phase partitioning and aliquots from the detergent-rich (DT) and aqueous (AQ) phases were
immunoblotted and probed with 172 polyclonal anti-PrP antibody (1:4000). (B) Aliquots of the
CEP-HSS and brain homogenates (Brain) were separated by SDS/PAGE and immunoblotted
with an anti-CRD antibody (1:2000). Phospholipase C-solubilized porcine MDP was used as a
positive control for the antibody. The same membranes were then stripped and reprobed with
the anti-PrP antibody.

no change in its molecular mass under non-reducing and reducing
conditions (Figure 8B).
Since the ‘soluble’ PrP present in the male reproductive fluid is
reactive with an antibody directed against the C-terminal sequence
that bears the GPI-anchor site [13], it was of interest to investigate
whether it also retained the GPI anchor. It has been shown that
GPI-anchored PrP is found in the detergent-rich phase after Triton
X-114 phase partitioning, but remains in the aqueous phase when
the GPI anchor is absent [22,27]. After treatment with PI-PLC,
we subjected the CEP-HSS to phase separation by Triton X-114
(Figure 9A). In the absence of PI-PLC, the ‘soluble’ PrP present
in the CEP-HSS partitioned into the detergent-rich phase and
remained in this phase following treatment with PI-PLC. This
was not due to its association with other complex members, as
treatment with Triton X-114 resulted in the disruption of the
complex and clusterin being partitioned into the aqueous phase.
Similar results were obtained when the purified complex was used
in the place of CEP-HSS (results not shown).
These results suggested that the GPI anchor of the ‘soluble’
PrP was resistant to cleavage by PI-PLC. This was supported by
results obtained using the anti-CRD antibody that detects the
phospholipase-cleaved form of GPI-bearing proteins [17,22].
The anti-CRD antibody was able to detect the PrP from scrapieinfected sheep brain when the extract was treated with PI-PLC,
and PI-PLC-solubilized porcine MDP used as a positive control
(Figure 9B). However, it failed to detect PrP from CEP-HSS after
PI-PLC treatment. This was not due to a lack of protein, as PrP was
readily detected by an anti-PrP antibody in these samples. Again,
similar results to the CEP-HSS were obtained when the purified
complex was used in this experiment (results not shown). Also,
no apparent change in the relative SDS/PAGE mobility of PrP
from CEP-HSS or the purified complex was observed following
treatment with PI-PLC. In contrast, when brain extracts from

PrP is a 28 kDa protein known to exist in a number of different
glycoforms and, in the male reproductive fluid, sugar moieties
can add up to 15–18 kDa to its apparent molecular mass [13].
In previous studies, we have demonstrated that a part of the PrP
present in this fluid was linked to exosome-like vesicles and that
a large part remained in a ‘soluble’ state in the bulk phase [13].
In the present study, using both HPLC and sucrose-gradient sedimentation (two purification methods based on different physical
principles), we show that this ‘soluble’ PrP behaves like a highmolecular-mass protein of more than 350–400 kDa. We also
observed that the PrP always co-purifies with the same proteins,
which were identified by both MS and immunoblotting, suggesting that they were associated in a supramolecular structure.
A number of studies have been conducted aimed at identifying
PrP-interacting proteins, since they should help to provide insights
into the physiological functions of PrP and/or explain how PrPC
can be transformed into PrPSC . However, a number of these studies
utilized molecular biology approaches (such as yeast two-hybrid
systems and expression library screening) or in vitro assays, and
thus some of these interactions may not be significant in vivo. One
protein shown to interact with PrP in a body fluid is plasminogen,
which binds PrPC and PrPSC from different species [29–31]. Here,
a ‘soluble’ PrP form that is naturally found in the epididymal fluid
was found to co-purify with a number of hydrophobic proteins,
as well as with proteins thought to interact with hydrophobic
domains and/or lipids. This ‘soluble’ PrP exists in a different form
than that present in spermatozoa or their cytoplasmic droplets
[13,32], and arises from its secretion into the cauda epididymis
[8].
Some of the proteins found to co-purify with ‘soluble’ PrP
are already known to exist in high-molecular-mass complexes in
other bodily fluids. For example, clusterin, which can act as an
extracellular chaperone [33,34], is a well-characterized apolipoprotein [35–37] and is found in relatively high concentrations
in male reproductive fluid and in the brain [38]. Interestingly, in
blood, this protein is typically associated with lipoprotein vesicles
[35]. Many of the reported biological ligands of clusterin are
significantly hydrophobic, and clusterin has been shown to bind
to hydrophobic regions of exposed proteins to solubilize them and
protect then from precipitation [34,39]. A link between clusterin
expression and PrP has been suggested previously by studies in
which clusterin has been co-localized to fibril-forming deposits
[40,41], and the aggregation of the prion peptide 106–126 has
been shown to be prevented by clusterin [42]. Recently, it
has been shown that the clusterin knockout mouse has a shorter
incubation time and different PrPSC deposition than wild-type
mice when infected with BSE, suggesting a role for clusterin in
the compartmentalization of PrPSC [43].
BPI plays a role in immune protection from Gram-negative
bacteria and, recently, the mRNA for this protein was found to be
expressed in the testis and epididymis in mice [44]. It is a member
of the lipid transfer/lipopolysaccharide-binding protein gene
family and is related to two mammalian lipid transport proteins,
CETP (cholesteryl ester transfer protein) and PLTP (phospholipid
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transfer protein) [45]. It has been shown to bind phospholipids
and may itself have lipid transfer activity, enabling phospholipid transfer from membranes to high-density lipoprotein
particles [45]. β-Galactosidase and mannosidase have been shown
to associate with membrane vesicles in the male reproductive fluid
[46,47], and to be enzyme-active within these vesicles [46,48].
Cauxin, a carboxylesterase-like enzyme, is present in the kidneys
and urine of domestic cats [18]. Cauxin’s biological role is yet
to be determined, but, since the protein identified here retains
its enzymatic activity within this complex, it may be involved in
lipid and cholesterol processing such as cholesterol esterification.
This is the first report that a cauxin-like protein is present in the
male reproductive fluid and associates with PrP. We also found
that a 17 kDa hydrophobic protein, which we have previously
characterized [19], also associates with this protein complex. This
protein shows no homology with proteins from current databases
and its biochemical properties showed that it is a very hydrophobic
compound.
We have partially characterized some features of this supramolecular association. First, it involves disulphide-bond-containing proteins, including clusterin and the cauxin-like protein, and
addition of 2-mercaptoethanol disrupts the complex, indicating
a structural role for these proteins. Secondly, the most abundant
proteins do not bind calcium, as evidenced by the lack of change
in the electrophoretic mobility of these proteins upon addition of
EGTA or CaCl2 to the sample buffer (H. Ecroyd and J.-L. Gatti,
unpublished work). Finally, the interactions between the different
proteins are not ionic, as evidenced by the inability of high salt
concentrations (up to 1 M) to cause its dissociation.
All the data obtained in the present study suggest that the PrP
is associated with the other components due to their hydrophobic
properties and not through direct protein–protein interactions, in
a similar manner to proteins associated in lipoprotein vesicles
found in blood plasma and cerebrospinal fluid. For example,
the fractions following gel-filtration HPLC, in which the PrP
complex was found, are similar to those in which low-density
lipoprotein vesicles elute from cerebrospinal fluid [37]. These
lipid vesicles have specific lipid and protein compositions and
different combinations of lipid and protein produce lipoprotein
particles of different density and size. Although we have not
specifically addressed its lipid content, we noted the evidence of
large amounts of lipid in the PrP-associated complex when it was
run on SDS/polyacrylamide gels and subsequently silver-stained
to visualize the proteins. However, even when a hydroxylamine
treatment, aimed at removing any lipid directly attached to
the inositol ring [49], was used before PI-PLC treatment, we
found that ‘soluble’ PrP was still unreactive with the anti-CRD
antibody (results not shown). Together, our results suggest that
‘soluble’ PrP retains its GPI anchor, which is resistant to PI-PLC
cleavage in a similar manner to that reported for another GPIcontaining protein present in epididymal fluid, PH20 [50]. Definitive evidence towards the presence of a GPI anchor on this
‘soluble’ form of Prp will require experiments involving the direct
structural determination of the anchor, using techniques such as
MS and/or metabolic labelling.
The existence of lipoprotein vesicles may enable the association
of PrP with this complex through its GPI anchor and also facilitate the resistance of this anchor to PI-PLC cleavage. Also,
its incorporation into these vesicles may not be dependent on
direct protein–protein interactions with other members. Evidence
for this latter proposal is supported by our finding that immunoprecipitation with antibodies fails to bring down other complex
members (H. Ecroyd and J.-L. Gatti, unpublished work). We
suggest that this is probably due to the proteins having a much
higher affinity for the antibodies than other proteins in the
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lipoprotein complex. Immunoprecipitation is therefore likely to
cause the protein to be simply displaced from the vesicle and even
vesicle disassembly. Further investigations will be necessary to
detail the nature of the lipid vesicle that maintains these proteins
together.
In conclusion, here we report the identification and the biochemical characterization of a ‘soluble’ PrP-associated highmolecular-mass complex from male reproductive fluid that
resembles micelles or lipoprotein vesicles. We have identified a
number of proteins present in this structure, which are in agreement with this hypothesis. To date, the presence of such lipoprotein vesicles in the epididymal fluid has not been described, but
their existence could explain how numerous hydrophobic proteins
found in this fluid remain in a soluble state and how some are
transferred between cells [51]. They may also enable clearance
of hydrophobic proteins in a state that prevents their precipitation
and aggregation, a process particularly relevant to PrP transport in
terms of disease propagation. As such, this purified PrP-associated
complex may provide a valuable model to study a mechanism by
which PrP could be transferred between cells.
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